A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
Introduction
Gastrinomas are functional neuroendocrine tumors of the gastroenteropancreatic system that cause the ZollingerEllison syndrome. In patients with sporadic gastrinoma, surgical resection is considered to be the first-line treatment (1) (2) (3) (4) . However, it is known that patients with metastases of gastrinoma, which are usually located in the liver, have markedly shortened survival, and there is controversy about the indications for surgery (2) (3) (4) (5) (6) . It has also been reported that about 50% of patients with multiple endocrine neoplasia (MEN) type 1 have gastrinoma and half of them ultimately develop metastases (7) (8) (9) . And recently an epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan reported that 25 percent of gastrinoma was accompanied by MEN-1 (10) . In addition to metastasis itself, poor prognostic factors for patients with gastrinoma are a large primary tumor (>3 cm in diameter), bone metastases, and inadequate control of the hypersecretion of gastric acid (4, 11, 12) . Though chemotherapy, interferon, embolization, and chemoembolization have all been tried, the 5-year survival rate of patients with metastatic gastrinoma is still reported to be only 20-40% (11, (13) (14) (15) .
A long-acting somatostatin analogue (octreotide LAR) has an antitumor effect on gastrinoma, and the National Comprehensive Cancer Network (NCCN) clinical practice guideline 2009 recommends octreotide for patients with metastatic gastrinoma (16) . However, it has been reported that the response rate is only 53%, with the mean duration of response being 25.0 months (17) . So far, there is no established treatment for nonresponders.
Here, we present a rare patient with metastatic gastinoma and MEN-1 who has shown a good response to octreotide for more than 7 years. calcidol. At the age of 27 years, she was injured in a traffic accident and underwent amputation of her right foot. In the same year, she suffered from meningitis because of a cerebrospinal fluid fistula that had been caused by a combination of her previous surgery and invasion by the residual prolactinoma. The following year she stopped bromocriptine therapy for the residual prolactinoma in order to block the cerebrospinal fluid fistula by allowing growth of the tumor, but she still suffered from attacks of meningitis. There was no family history of endocrine diseases. Hormonal evaluation on admission revealed a marked increase of gastrin to 1,588 pg/mL (normal range: 30-150 pg/mL). However, enhanced computed tomography (CT) and magnetic resonance imaging (MRI) showed no evidence of a tumor in or around the pancreas. Because she and her family refused further investigations such as selective arterial secretin injection test and angiography, she was followed up with oral administration of a proton pump inhibitor. During the next year, her nausea and vomiting became worse and she was readmitted to our hospital. At the second admission, her height was 151.0 cm, weight was 97.3 kg (82 kg at the first admission), and BMI was 42. Her pulse rate was 70/min (regular), blood pressure was 100/70 mmHg, and body temperature was 36.3°C. Her consciousness was clear. Her bulbar conjunctiva was not icteric, the palpebral conjunctiva was not pale, and the light reflex was prompt and complete. On auscultation, her lungs and heart were normal. There was no abnormal lactation. Her abdomen was full, but there were no abnormal findings on palpation. She did not have any neurological abnormalities. Laboratory data obtained at the second admission are shown in Table 1 . Routine laboratory tests showed slight elevation of inflammatory parameters and dyslipidemia. Hormonal evaluation revealed an increase of prolactin to 4,200 ng/mL (normal range: 1.5-15 ng/mL) and an increase of gastrin to 2,900 pg/mL (normal range: 30-150 pg/mL), along with a decrease of growth hormone to 0.28 ng/mL (normal range: 0.66-3.68 ng/mL), LH to <0.5 mIU/mL (normal range: 1-8 m/mL), FSH to <0.5 mIU/mL (normal range: 3-15 mIU/mL), and glucagon to 230 pg/mL (normal range: 320-430 pg/mL).
T a b l e 1 . L a b o r a t o r y Da t a o n t h e S e c o n d Ad mi s s i o n
After admission, enhanced CT, the selective intra-arterial secretin injection test, and selective angiography were carried out. This time, enhanced CT scans of the abdomen revealed multiple tumors located in the pancreas, the duodenal cap, and the 2 nd-3 rd parts of the duodenum (Fig. 1A and B) . Selective angiography demonstrated tumor stains in the head of the pancreas, duodenal cap, 2nd-3rd parts of the duodenum, and left lobe of the liver (Fig. 1C) . In the selective arterial secretin injection test, there was a significant increase of gastrin after injection via the superior mesenteric artery, gastroduodenal artery, splenic artery, and right hepatic artery (Fig. 2) . As several tumors (<15 mm in diameter) were observed in the duodenum by endoscopy, endoscopic biopsy was carried out (Fig. 3) . On histological examination, tumor cells formed solid areas in the lamina propria of the duodenal mucosa. The tumor cells were monotonous with oval nuclei and rare mitotic figures. The Ki-67/MIB1 proliferation index was only 0.5%. Immunohistochemical staining showed that the tumor cells were positive i c a r t e r y , g a s t r o d u o d e n a l a r t e r y ,  s p l e n i c a r t e r y , a n d r i g h t h e p a t i c a r t e r y . for gastrin, neuron-specific enolase, chromogranin A, and SSTR2 while being negative for insulin, somatostatin, and glucagon. Lymphatic invasion was clearly indicated by D2-40 immunostaining. Based on these findings and her history, a diagnosis of metastatic gastinoma associated with MEN-1 was made. She did not consent to genetic testing.
F i g u r e 1 . E n h a n c e d c o mp u t e d t o mo g r a p h y ( CT ) i ma g e s o f t h e a b d o me n o n t h e s e c o n d a d mi s s i o n a r e s h o wn . Mu l t i p l e t u mo r s i n t h e d u o d e n a l c a p ( 1 A w h i t e a r r o w s ) a n d i n t h e 2 n d -3 r d p o r t i o n s o f t h e d u o d e n u m ( 1 B w h i t e a r r o w s ) we r e d e t e c t e d . S e l e c t i v e a n g i o g r a p h y d e mo n s t r a t e d t u mo r s t a i n s i n t h e h e a d o f t h e p a n c r e a s , d u o d e n a l c a p , 2 n d -3 r d p o r t i o n s o f t h e d u o d e n u m, a n d l e f t l o b e o f t h e l i v e r ( 1 C w h i t e a r r o w s ) .

F i g u r e 2 . T h e s e l e c t i v e a r t e r i a l s e c r e t i n i n j e c t i o n t e s t s h o we d t h e s i g n i f i c a n t i n c r e a s e o f g a s t r i n a f t e r i n j e c t i o n v i a t h e s u p e r i o r me s e n t e r
After making the diagnosis, we recommended her to have an operation (combined pancreaticoduodenectomy and hepatectomy), but she and her family did not agree. She chose medical treatment with subcutaneous injection of the somatostatin analogue octreotide at a dose of 50 μg every 12 hours. After the start of octreotide treatment, her symptoms were resolved and the serum gastrin level showed a significant decrease. The serum prolactin level did not change and there were no side effects from this treatment. Changes in serum hormone levels are shown in Fig. 4 . During the first two years, she remained on 50 μg of octreotide twice a day. As a result, her serum gastrin level was suppressed, but her prolactin level was not. After that, she decided to stop octreotide therapy herself and the gastrin level markedly increased to 2,300 ng/mL. Therefore, her treatment was changed to long-acting intramuscular octreotide once a month. Subsequently, her serum gastrin level has been suppressed and it has remained in the range of 300 to 500 ng/ mL for 5 years (Fig. 4) .
Sequential changes of the pancreatic and duodenal tumors on enhanced abdominal CT are shown in Fig. 5 , indicating that her tumors have grown very slowly. Endoscopy was repeated seven years later and confirmed that there were no macroscopic changes of the tumors. In order to investigate the reason for the long duration of her response, staining of tumor tissue samples for the somatostatin receptor (SSTR) was done, and both the samples obtained at the second admission and those seven years later showed very strong expression of SSTR2. The Ki-67/MIB1 proliferation index was only 0.5%.
The patient is currently active and able to continue working, while receiving octreotide LAR once a month. Her gas-
F i g u r e 3 . I mmu n o h i s t o c h e mi s t i c a l a n a l y s i s o f t h e d u o d e n a l t u mo r wh i c h wa s o b t a i n e d b e f o r e t h e o c t r e o t i d e i n j e c t i o n . Hi s t o l o g i c a l l y , t u mo r c e l l s f o r me d s o l i d a r e a s i n t h e l a mi n a p r o p r i a o f t h e d u od e n a l mu c o s a ( 3 A) . T h e t u mo r c e l l s we r e mo n o t o n o u s wi t h o v a l n u c l e i a n d r a r e mi t o t i c f i g u r e s ( 3 B ) . I mmu n o h i s t o c h e mi c a l s t a i n i n g s h o we d t h a t t u mo r c e l l s we r e p o s i t i v e f o r g a s t r i n ( 3 C) . D2 -4 0 mo n o c l o n a l a n t i b o d y r e v e a l e d a t u mo r c e l l c l u s t e r o u t l i n e d b y D2 -4 0 p o s i t i v e e n d o t h e l i a l c e l l s , i n d ic a t i n g l y mp h a t i c i n v a s i o n ( 3 D) .
F i g u r e 4 . T h e c l i n i c a l c o u r s e o f t h e p a t i e n t .
trin level remains around 650 pg/mL and she has no symptoms, such as nausea or vomiting.
Discussion
We presented a rare case of metastatic gastinoma with MEN-1, in whom a good response to octreotide has been maintained for more than seven years. MEN-1 is an autosomal dominant tumor syndrome. The MEN-1 gene acts as a tumor suppressor gene and is expressed in a broad range of endocrine and non-endocrine tissues (18, 19) . More than 90% of patients who inheririt MEN-1 develop at least one manifestation of this syndrome by the age of 30 years (7). Neuroendocrine tumors of the upper gastrointestinal tract, especially gastrinoma, are a major cause of morbidity and mortality in patients with MEN-1 (19, 21, 22) . In MEN-1 patients, the source of gastrin hypersecretion is usually occult, arising from multiple duodenal and/or pancreatic neuroendocrine lesions that are mainly microscopic in size, suggesting that surgical intervention is very difficult and other methods for controlling the serum gastrin level is essential (9, 23). However, it is reported that the gastrinoma of
F i g u r e 5 . E n h a n c e d c o mp u t e d t o mo g r a p h y ( CT ) i ma g e s o f t h e a b d o me n o n t h e s e c o n d a d mi s s i o n ( 5 A) , t h r e e y e a r s l a t e r ( 5 B ) , f i v e y e a r s l a t e r ( 5 C) , a n d s e v e n y e a r s l a t e r ( 5 D) , i n d i c a t e t h a t h e r t u mo r s h a v e g r e w v e r y s l o wl y .
MEN-1 patients is usually present in the duodenum and it rarely metastasizes to liver. On the contrary, pancreatic tumors are usually non-functioning and often metastasize to liver (24, 25) . Recently a new pancreas-preserving total duodenectomy method was developed and it has been reported to be effective, which might offer a lower risk than pancreaticoduodenectomy (25) . This new method and/or partial hepatectomy might provide a new therapeutic alternative in this case.
To predict the biological behavior of neuroendocrine tumors, the World Health Organization (WHO) proposed several factors as prognostic criteria in 2004, including tumor size vessel invasion, mitotic activity, and the Ki67/MIB1 proliferation index (26) . Ki67/MIB1 is a protein that can be detected during all active phases of the cell cycle (G1, S, G 2, and mitosis), while it is absent from resting cells (G0) (27) . Therefore, Ki67/MIB1 expression is associated with cell proliferation and has been widely validated as a prognostic marker for various tumors (27, 28) . In this patient, the duodenal tumor was about 3 cm in size and there was lymphovascular invasion, although the tumor cells were well differentiated. Accordingly, the tumor was classified as a well-differentiated neuroendocrine carcinoma. However, the Ki67/MIB1 proliferation index of this tumor was only 0.5%, which might have been one reason for the good prognosis.
Another reason might have been the long-term beneficial effect of octreotide on the gastrinoma in our patient. Octreotide is an analogue of the cyclic polypeptide somatstatin (29) . Somatostatin suppresses the activity of various peptide hormones, including those involved in pancreatic secretion, neurotransmission in the central nervous system, and gut motility (30) . These actions of somatostatin are mediated by six receptors (SSTRs; SSTR1, 2a, 2b, 3, 4, and 5), which are expressed by neuroendocrine tumors as well as throughout the body and promote both antiproliferative and proapoptotic effects via common signaling pathways such as inhibition of adenylate cyclase or the activation of phosphatases (29, 30) . Certain receptors are reported to be associated with modulation of inward rectifying K+ channels (SSTR2, 3, 4, 5), voltage-dependent Ca 2+ channels (SSTR1, 2), and the Na + /H + exchanger (SSTR1) (31). Octreotide demonstrates strong affinity for SSTR2 and weak affinity for SSTR1, 3, 4, and 5 (32) . Though the role of each SSTR in regulating the human endocrine system has not been thoroughly elucidated, there have already been some reports that suggested the efficacy of octreotide in patients with gastrinoma. Kumar et al demonstrated that SSTR 1, 2, and 5 were strongly expressed in the human endocrine pancreas, whereas the expression of SSTR3 and 4 was weak (33) . Piqueras et al also reported that somatostatin modulated the gastrin/enterochromaffin-like cell/parietal cell axis through SSTR2 (34) . Therefore, since octreotide is a strong agonist of SSTR2, it can be expected to have antitumor activity. In fact, the 2009 NCCN clinical practice guideline recommends octreotide for patients with metastatic gas-trinoma.
In this case, the tumor showed no change in the strong expression of SSTR2 for at least seven years, which could have contributed to the long-lasting response to octreotide. It has been reported that the response rate to octreotide in patients with malignant gastrinoma is 53% and the mean duration of response is 25.0 months (17) , probably because of down-regulation of the target SSTR. Therefore, the good response and long-term expression of SSTR2 in the present case are thought to be rare.
According to the NCCN guideline for neuroendocrine tumors, the next treatment recommended after octreotide is embolization, chemoembolization, or chemotherapy such as streptozotocin and doxorubicin (16) . However, effective management for metastatic gastrinoma remains to be established. The 5-year survival rate of these patients is reported to be only 20-40% (11, (13) (14) (15) . In addition, treatment with streptozotocin and doxorubicin is currently not approved in Japan. A novel multireceptor somatostatin analog, pasireotide (SOM230), is now raising expectations as a new therapeutic agent for metastatic gastrinoma. A activation of SSTR 1, 2, 3 and 5 is known to induce the cell cycle arrest, and SSTR2 and 3 induce apoptosis (35) . SOM230 not only shows strong binding to SSTR2, but also to SSTR1, 3 and 5, to which octreotide only binds weakly (36) . Therefore, though SOM230 has not yet been approved in Japan, it could be a promising candidate for clinical application where octreotide is shown to be weak or even ineffective.
In the future, we will be able to choose somatostatin analogs according to SSTR subtype expression by the tumor. Therefore, in patients with neuroendocrine tumors, it seems to be important to not only analyze endocrine markers (such as neuron-specific enolase, chromogranins, synaptophysin, etc.) and the Ki67/MIB1 proliferation index, but also the subtype of SSTR.
